ASX-Dividend-Report-Banner

First half of 2023: Boehringer Ingelheim sees strong growth and expansion in key therapy areas

August 01, 2023 06:30 PM AEST | By Businesswire India
Follow us on Google News: https://kalkinemedia.com/resources/assets/public/images/google-news.webp
 First half of 2023: Boehringer Ingelheim sees strong growth and expansion in key therapy areas
Image source: Businesswire India
Business Wire India
  • Areas of progress include rare skin diseases, cardio-renal-metabolic diseases, and immuno-oncology
  • Jardiance® and NexGard® portfolios drive strong growth
  • First half 2023 net sales up 9.7 percent at 12.2 billion EUR year on year and currency-adjusted
 

Boehringer Ingelheim, a leading research-driven biopharmaceutical company, continues to advance its pipeline in both Human Pharma and Animal Health expanding across its key therapy areas.

 

Currency-adjusted net sales rose by 9.7 percent to 12.2 billion EUR driven by high demand for medications during the first six months of 2023, driven by strong momentum in Jardiance® for Human Pharma and NexGard® for Animal Health.

 

“True innovation addressing high unmet patients’ needs has enabled us to reach ever more patients in the first half of this year,” said Hubertus von Baumbach, Chairman of the Board of Managing Directors. “Persistent and above-average investments in our pipeline during the last years have resulted in many new treatment options for patients in the years to come, thus transforming lives for generations.”

 

Boehringer Ingelheim continued expanding its pipeline portfolio through in-house as well as external innovation – 15 new innovation partnerships were formed in areas such as cancer immunology, fibrotic lung diseases and retinal diseases. Overall, the company has committed to invest 25 billion EUR in Research & Development and an additional 7 billion EUR for new production technologies over the next five years.

 

Net sales in Human Pharma were up 11.3 percent (currency-adjusted) at 9.6 billion EUR in the first half of the year, mainly driven by the Jardiance® family at 3.5 billion EUR and the respiratory medicine OFEV® at 1.7 billion EUR.

 

Jardiance® experienced strong momentum in the first six months of 2023. It is expected to grow following additional regulatory action for treatment of chronic kidney disease. Worldwide 850 million people1 live with this disease. With the addition to existing indications in type 2 diabetes and heart failure, Jardiance® will potentially be able to help manage cardio-renal-metabolic conditions. Over 1 billion people live with cardio-renal-metabolic conditions globally2.

 

In oncology, the company’s MDM2-p53 agonist brigimadlin has advanced into the pivotal trial for the treatment of dedifferentiated liposarcoma, a rare cancer with limited treatment options so far. The clinical development of two additional investigational therapies (zongertinib, also known as BI 1810631, and BI 764532) from the oncology pipeline has been accelerated based upon positive early clinical data.

 

The PDE4b agonist BI 1015550 is now in two clinical Phase III trials for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and Progressive Pulmonary Fibrosis. Patient recruitment for trial investigating BI 10105550 in IPF is well ahead of plan.

 

“We have become very successful in bringing new products through our pipeline addressing patients’ needs faster,” said Michael Schmelmer, Member of the Board of Managing Directors, responsible for Finance & Group Functions. “We expect to further increase our R&D spending as clinical trials progress into late-stage phases.”

 

Animal Health recorded growth in Pets and Livestock, with sales increasing by 3.8 percent (currency-adjusted) to 2.5 billion EUR in the first six months of the year. Net sales of NexGard®, a flea and tick prevention for dogs and cats, increased 9.2 percent (currency-adjusted) to 644 million EUR, while Ingelvac Circoflex®, a vaccine used to protect pigs against porcine circovirus type 2, rose 8.7 percent to 127 million EUR.

 

In addition, the company complemented its market-leading NexGard® portfolio through FDA approvals for NexGard® PLUS, a new monthly combination product for dogs that protects against fleas, ticks, heartworm disease, roundworms and hookworms, and NexGard® COMBO, the first-and-only feline broad-spectrum parasite protection that treats tapeworms.

 

The Animal Health business has made further progress in the pipeline development in infectious and non-infectious diseases for Pets and Livestock and is preparing for the launch of a highly innovative oral product for diabetes in cats.

 

For the remainder of the year Boehringer Ingelheim expects more progress in its innovation efforts, such as data readout for a Phase III trial with empagliflozin in patients after myocardial infarction and upcoming regulatory action for OFEV® in children and adolescents between 6-17 years with interstitial lung disease.

 

Looking forward, the company aims to achieve more than 30 new medical approvals in Human Pharma by 2029 and expects around 20 product launches in Animal Health through 2025.

 

Click here for the full release: Boehringer Ingelheim half-year results 2023 | Boehringer Ingelheim (boehringer-ingelheim.com)

 

References:

 

1Li P, et al. Braz J Med Biol Res. 2020; 53(3): e9614.

 

2Schechter, M. et al. Cardiovasc Diabetol. 2022:21;104.

 

 

"Kalkine Media dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum."

Section 1.10.32 of "de Finibus Bonorum et Malorum", written by Cicero in 45 BC

"Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium do Kalkine que laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo. Nemo enim ipsam voluptatem quia voluptas sit aspernatur aut odit aut fugit, sed quia consequuntur magni dolores eos qui ratione voluptatem sequi nesciunt. Neque porro quisquam est, qui do Kalkine Media quia dolor sit amet, consectetur, adipisci velit, sed quia non numquam eius modi tempora incidunt ut labore et dolore magnam aliquam quaerat voluptatem. Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam, nisi ut aliquid ex ea commodi consequatur? Quis autem vel eum iure reprehenderit qui in ea voluptate velit esse quam nihil molestiae consequatur, vel illum qui do Kalkine eum fugiat quo voluptas nulla pariatur?"

1914 translation by H. Rackham

"But I must explain to you how all this mistaken idea of denouncing pleasure and praising pain was born and I will give you a complete account of the system, and expound the actual teachings of the great explorer of the truth, the master-builder of human happiness. No one rejects, dislikes, or avoids pleasure itself, because it is pleasure, but because those who do not know how to pursue pleasure rationally encounter consequences that are extremely painful. Nor again is there anyone who loves or pursues or desires to obtain pain of itself, because it is pain, but because occasionally circumstances occur in which toil and pain can procure him some great pleasure. To take a trivial example, which of us ever undertakes laborious physical exercise, except to obtain some advantage from it? But who has any right to find fault with a man who chooses to enjoy a pleasure that has no annoying consequences, or one who avoids a pain that produces no resultant pleasure?"

1914 translation by H. Rackham

"But I must explain to you how all this mistaken idea of denouncing pleasure and praising pain was born and I will give you a complete account of the system, and expound the actual teachings of the great explorer of the truth, the master-builder of human happiness. No one rejects, dislikes, or avoids pleasure itself, because it is pleasure, but because those who do not know how to pursue pleasure rationally encounter consequences that are extremely painful. Nor again is there anyone who loves or pursues or desires to obtain pain of itself, because it is pain, but because occasionally circumstances occur in which toil and pain can procure him some great pleasure. To take a trivial example, which of us ever undertakes laborious physical exercise, except to obtain some advantage from it? But who has any right to find fault with a man who chooses to enjoy a pleasure that has no annoying consequences, or one who avoids a pain that produces no resultant pleasure?"

To keep reading, please log in to your account, create a free account, or simply fill out the form below.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

Recent Articles

Investing Tips

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.